Physician profile
Donald E Rediker
NPI 1144207333
$8,877.06
in general payments reported to CMS, 2019-2025
37 companies · $1,329 in 2025
The $1,329 reported for 2025 was more than what 76% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,519 · 2020: $612 · 2021: $204 · 2022: $1,787 · 2023: $1,686 · 2024: $740 · 2025: $1,329.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,755.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,755.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,213.14 | 2019-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $1,057.94 | 2019-2025 | |
| Boston Scientific Corporation | $932.80 | 2019-2025 | General - Crm_crm, Lux-Dx Insertable Cardiac Monitor, Watchman Flx |
| Alnylam Pharmaceuticals INC. | $594.82 | 2019-2025 | Amvuttra, Onpattro |
| Biotronik INC. | $591.65 | 2019-2020 | |
| Aop Health US, LLC | $487.65 | 2025 | Rapiblyk |
| E.R. Squibb & Sons, L.L.C. | $397.17 | 2019-2025 | Camzyos, Eliquis |
| Pfizer INC. | $383.66 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $381.05 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $335.11 | 2019-2024 | Xarelto |
| Merck Sharp & Dohme LLC | $272.12 | 2022-2024 | Verquvo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $244.75 | 2019-2025 | Jardiance |
| Medtronic, INC. | $213.27 | 2021-2023 | Linq II |
| Astrazeneca Pharmaceuticals LP | $208.89 | 2019-2024 | Farxiga, Wainua |
| Medtronic Vascular, INC. | $191.19 | 2019-2020 |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donald Rediker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.